The ruling from the Paris appeals court stems from a 2013 decision by France’s competition authority that fined Sanofi 40.6 million euros for acting against generic competitors of Plavix between 2009 and 2010.
Sign up here.
Sanofi did not immediately respond to a Reuters’ request for comment.
The appeals court found that the effects of the anti-competitive practices persisted among healthcare professionals until 2021, despite only lasting five months.
Plavix was France’s most reimbursed drug in 2008, costing the healthcare system 625 million euros, the court said.
The appeals court awarded CNAM 126.2 million euros for additional reimbursement costs and pharmacy fees and 24.5 million euros in additional financial damages.
($1 = 0.8510 euros)
Reporting by Gianluca Lo Nostro